Isabelle Lamrissi-Garcia
Overview
Explore the profile of Isabelle Lamrissi-Garcia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
497
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boutin J, Genevois C, Couillaud F, Lamrissi-Garcia I, Guyonnet-Duperat V, Bibeyran A, et al.
Mol Ther Oncol
. 2024 Apr;
32(1):200772.
PMID: 38596305
Thanks to its very high genome-editing efficiency, CRISPR-Cas9 technology could be a promising anticancer weapon. Clinical trials using CRISPR-Cas9 nuclease to edit and alter immune cells are ongoing. However, to...
2.
Prat F, Toutain J, Boutin J, Amintas S, Cullot G, Lalanne M, et al.
Stem Cell Reports
. 2020 Aug;
15(3):677-693.
PMID: 32795423
CRISPR/Cas9 is a promising technology for gene correction. However, the edition is often biallelic, and uncontrolled small insertions and deletions (indels) concomitant to precise correction are created. Mutation-specific guide RNAs...
3.
Blouin J, Ged C, Lalanne M, Lamrissi-Garcia I, Morice-Picard F, Costet P, et al.
Blood
. 2020 Jul;
136(21):2457-2468.
PMID: 32678895
Congenital erythropoietic porphyria (CEP) is an inborn error of heme synthesis resulting from uroporphyrinogen III synthase (UROS) deficiency and the accumulation of nonphysiological porphyrin isomer I metabolites. Clinical features are...
4.
Lefebvre T, Millot S, Richard E, Blouin J, Lalanne M, Lamrissi-Garcia I, et al.
Biochem Biophys Res Commun
. 2019 Oct;
520(2):297-303.
PMID: 31601421
Clinical severity is heterogeneous among patients suffering from congenital erythropoietic porphyria (CEP) suggesting a modulation of the disease (UROS deficiency) by environmental factors and modifier genes. A KI model of...
5.
Cullot G, Boutin J, Toutain J, Prat F, Pennamen P, Rooryck C, et al.
Nat Commun
. 2019 Mar;
10(1):1136.
PMID: 30850590
CRISPR-Cas9 is a promising technology for genome editing. Here we use Cas9 nuclease-induced double-strand break DNA (DSB) at the UROS locus to model and correct congenital erythropoietic porphyria. We demonstrate...
6.
Bedel A, Beliveau F, Lamrissi-Garcia I, Rousseau B, Moranvillier I, Rucheton B, et al.
Stem Cells Transl Med
. 2017 Feb;
6(2):382-393.
PMID: 28191782
Iatrogenic tumorigenesis is a major limitation for the use of human induced pluripotent stem cells (hiPSCs) in hematology. The teratoma risk comes from the persistence of hiPSCs in differentiated cell...
7.
Rouault-Pierre K, Lopez-Onieva L, Foster K, Anjos-Afonso F, Lamrissi-Garcia I, Serrano-Sanchez M, et al.
Cell Stem Cell
. 2013 Oct;
13(5):549-63.
PMID: 24095676
Hematopoietic stem and progenitor cells (HSPCs) are exposed to low levels of oxygen in the bone marrow niche, and hypoxia-inducible factors (HIFs) are the main regulators of cellular responses to...
8.
Ricard A, Pain C, Daubos A, Ezzedine K, Lamrissi-Garcia I, Bibeyran A, et al.
Exp Dermatol
. 2012 Apr;
21(6):411-6.
PMID: 22507556
We have hypothesised that melanocytes disappear in vitiligo because they are weakly attached to the epidermal basal membrane (melanocytorrhagy). In the epidermis, attachment of melanocytes to collagen IV is mediated...
9.
Robert-Richard E, Lalanne M, Lamrissi-Garcia I, Guyonnet-Duperat V, Richard E, Pitard V, et al.
J Gene Med
. 2010 Jun;
12(8):637-46.
PMID: 20586119
Background: Congenital erythropoietic porphyria (CEP) is a severe autosomal recessive disorder characterized by a deficiency in uroporphyrinogen III synthase (UROS), the fourth enzyme of the heme biosynthetic pathway. We recently...
10.
James C, Mazurier F, Dupont S, Chaligne R, Lamrissi-Garcia I, Tulliez M, et al.
Blood
. 2008 Jul;
112(6):2429-38.
PMID: 18612101
The JAK2V617F somatic point mutation has been described in patients with myeloproliferative disorders (MPDs). Despite this progress, it remains unknown how a single JAK2 mutation causes 3 different MPD phenotypes,...